Expanding Therapeutic Horizons: GLP-1 Receptor Agonists and SGLT2 Inhibitors in Overweight and Obese CFRD Adults

Author-deposited version of article originally published in Journal of Obesity & Weight Loss Therapy (2025)

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2025-08-25
DOI
https://doi.org/10.5281/zenodo.17148001
Primary Topic
Geochemistry and Geologic Mapping
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Expanding Therapeutic Horizons: GLP-1 Receptor Agonists and SGLT2 Inhibitors in Overweight and Obese CFRD Adults

Zenodo (CERN European Organization for Nuclear Research)
Geochemistry and Geologic Mapping
article

Expanding Therapeutic Horizons: GLP-1 Receptor Agonists and SGLT2 Inhibitors in Overweight and Obese CFRD Adults

article en

Abstract

Author-deposited version of article originally published in Journal of Obesity & Weight Loss Therapy (2025)

Zenodo (CERN European Organization for Nuclear Research)
University of Minnesota Medical Center (US)
Good health and well-being
Openalex Percentile: Top 39%
Geochemistry and Geologic Mapping
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Expanding Therapeutic Horizons: GLP-1 Receptor Agonists and SGLT2 Inhibitors in Overweight and Obese CFRD Adults · Zenodo (CERN European Organization for Nuclear Research) (2025) | TGRS Research Map | TGRS